Hao Dongting
Executive Chairperson
Board of DirectorsThe business, the people and the ownership behind SDAI.
Business overview
SDAI is an investment holding group that has entered the biotechnology industry. Its biotechnology activities include its subsidiary Beijing Blue Code Biotechnology, alongside the group’s other investment interests.
Listed security
Board & management
Executive Chairperson
Board of DirectorsExecutive Director
Board of DirectorsNon-Executive and Non-Independent Director
Board of DirectorsLead Independent Director
Board of DirectorsIndependent Director
Board of DirectorsIndependent Director
Board of DirectorsChief Executive Officer
Key ManagementRoles listed in ANNUAL REPORT 2025; current appointments are not independently verified.
Holdings
Direct interest 90,000,000 shares (21.2%); no deemed interest
Substantial shareholdersDirect interest 66,148,657 shares (15.6%); no deemed interest
Substantial shareholdersDirect interest 23,859,060 shares (5.6%); no deemed interest
Substantial shareholdersTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-03-16 · PDF p. 139
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| OOWAY GROUP LTD. | Rank 1; 90,000,000 shares; 21.19% | PDF p. 1392026-03-16 | |
| LIM WEE LI | Rank 2; 66,148,657 shares; 15.58% | PDF p. 1392026-03-16 | |
| CHEE TUCK HONG | Rank 3; 23,859,060 shares; 5.62% | PDF p. 1392026-03-16 | |
| CITIBANK NOMINEES SINGAPORE PTE LTD | Rank 4; 14,595,260 shares; 3.44% (nominee) | PDF p. 1392026-03-16 | |
| DBS NOMINEES (PRIVATE) LIMITED | Rank 5; 13,300,900 shares; 3.13% (nominee) | PDF p. 1392026-03-16 | |
| RAFFLES NOMINEES (PTE.) LIMITED | Rank 6; 12,412,000 shares; 2.92% (nominee) | PDF p. 1392026-03-16 | |
| OCBC SECURITIES PRIVATE LIMITED | Rank 7; 9,451,200 shares; 2.23% | PDF p. 1392026-03-16 | |
| HSBC (SINGAPORE) NOMINEES PTE LTD | Rank 8; 7,147,200 shares; 1.68% (nominee) | PDF p. 1392026-03-16 | |
| LIN SONGXIAN | Rank 9; 6,740,700 shares; 1.59% | PDF p. 1392026-03-16 | |
| CHIANG SIEW KAY | Rank 10; 5,521,000 shares; 1.30% | PDF p. 1392026-03-16 | |
| IFAST FINANCIAL PTE. LTD. | Rank 11; 5,167,700 shares; 1.22% | PDF p. 1392026-03-16 | |
| MAYBANK SECURITIES PTE. LTD. | Rank 12; 4,976,600 shares; 1.17% | PDF p. 1392026-03-16 | |
| ONG SOON LIONG @ONG SOON CHONG | Rank 13; 4,900,000 shares; 1.15% | PDF p. 1392026-03-16 | |
| PHILLIP SECURITIES PTE LTD | Rank 14; 4,875,800 shares; 1.15% | PDF p. 1392026-03-16 | |
| UOB KAY HIAN PRIVATE LIMITED | Rank 15; 4,772,736 shares; 1.12% | PDF p. 1392026-03-16 | |
| WONG HONG ENG | Rank 16; 4,603,308 shares; 1.08% | PDF p. 1392026-03-16 | |
| CHEE TAI CHIEW | Rank 17; 4,508,200 shares; 1.06% | PDF p. 1392026-03-16 | |
| POON POH MUI OR NG TZE KIONG | Rank 18; 4,300,000 shares; 1.01% | PDF p. 1392026-03-16 | |
| YANG XIANZHENG | Rank 19; 3,859,060 shares; 0.91% | PDF p. 1392026-03-16 | |
| PAMELA RACHEL KWAN KA FOONG | Rank 20; 3,659,060 shares; 0.86% | PDF p. 1392026-03-16 | |
Group structure
| Company | Market | Ownership interest |
|---|---|---|
| KHL (Hong Kong) LimitedHeld by the Company; Group proportion of equity interests, 2025 (comparative 2024 100)PDF p. 105 | Country/place of business: Hong Kong; Group equity interest 2025: 100%; 2024: 100%; NCI 2025: -, 2024: -; held by the Company; Investment holding | |
| SDAI Healthcare Pte. Ltd.Held by the Company; Group proportion of equity interests, 2025 (comparative 2024 100)PDF p. 105 | Country/place of business: Singapore; Group equity interest 2025: 100%; 2024: 100%; NCI 2025: -, 2024: -; held by the Company; Trading in specialist medical equipment and related supplies | |
| Hainan Blue Code Biotechnology Co. Ltd.Held by the Company; Group proportion of equity interests, 2025 (comparative 2024 100)PDF p. 105 | Country/place of business: China; Group equity interest 2025: 100%; 2024: 100%; NCI 2025: -, 2024: -; held by the Company; Technical consulting and development services, information consulting services, natural science research and development, general sales and retail; and e-commerce | |
| Kitchen Culture (Hong Kong) LimitedHeld by KHL; Group proportion of equity interests, 2025 (comparative 2024 70)PDF p. 105 | Country/place of business: Hong Kong; Group equity interest 2025: 70%; 2024: 70%; NCI 2025: 30%, 2024: 30%; held by KHL; Sales and distribution of kitchen system, kitchen appliances, wardrobe system, household furniture and appliances | |
| Kitchen Culture (China) LimitedHeld by KHL; Group proportion of equity interests, 2025 (comparative 2024 100)PDF p. 105 | Country/place of business: Hong Kong; Group equity interest 2025: 100%; 2024: 100%; NCI 2025: -, 2024: -; held by KHL; Dormant | |
| Blue Code Hainan (Healthcare) Co. Ltd.Held by HBCT; Group proportion of equity interests, 2025 (2024 shown as -)PDF p. 106 | Country/place of business: China; Group equity interest 2025: 100%; 2024: -; NCI 2025: -, 2024: -; held by HBCT; Dormant | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Liu Ting | Chief Executive Officer | PDF p. 10 | |
| Ng Kheng Jen | Acting Chief Financial Officer | PDF p. 10 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Interested Person Transaction | The Group does not have any interested person transactions (excluding less than S$100,000) in FY2025 that is disclosable under Rule 920(1)(a)(ii) of the Catalist Rules. | Group, FY2025 | PDF p. 62 |
| Mdm Hao Dongting | the value of the transaction (being the entry into 2024 Loan) is zero | Company, FY2025; interested person Mdm Hao Dongting; 2024 Loan, interest-free | PDF p. 62 |
| Mdm Hao Dongting | the value of the transaction (being the entry into 2025 Loan) is zero | Subsidiary Hainan Blue Code Biotechnology Co., Ltd, entered 7 March 2025; interested person Mdm Hao Dongting; interest-free working capital loan | PDF p. 62 |
| Salaries, bonuses and short-term benefits | 584,824 $ | The Group, 31 December 2025 (comparative 2024: 661,261) | PDF p. 123 |
| Executive Chairman and Chief Executive Officer of the Company | 495,750 $ | The Group, 31 December 2025 (comparative 2024: 411,219) | PDF p. 123 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Mdm Hao Dongting | 192,000 S$ | FY2025, individual director/CEO remuneration | PDF p. 51 |
| Mr Yap Koon Loong(2) | 216,000 S$ | FY2025, individual director/CEO remuneration | PDF p. 51 |
| Mr Lam Kwong Fai(1) | 70,000 S$ | FY2025, individual director/CEO remuneration | PDF p. 51 |
| Mr Tan Meng Shern(1) | 60,000 S$ | FY2025, individual director/CEO remuneration | PDF p. 51 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| total number of employees | 11 employees | Group, as at 31 December 2025 (31 December 2024: 7) · As at 2025-12-31 | PDF p. 25 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| 31. Subsequent events (a) | On 15 January 2026, a joint venture company, QCM Holdings Pte. Ltd. (“QCMH”), was established in Singapore. The Company holds a 55% stake, while Hubei Qiai owns 45% in QCMH. | Group | PDF p. 137 |
| 31. Subsequent events (b) | On 13 March 2026, the Company entered into six separate redeemable loan agreements | Company | PDF p. 137 |
| 31. Subsequent events (d) | On 13 March 2026, the Company entered into a supplemental agreement with a director to grant the extension of the $4,000,000 loan (Note 17(ii)) for an additional 18 months from its maturity date, 30 June 2026 | Company | PDF p. 137 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Corporate information